Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Tenaya Therapeutics announced positive interim results from its RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for patients with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Treatment with TN-401 resulted in substantial and consistent reductions in premature ventricular contractions (PVCs) in all six patients ev…